Uso, efectividad y seguridad de abiraterona en cáncer de próstata. [artículo]
Por: Caro Teller, José Manuel [Farmacia]
| Cortijo Cascajares, Susana [Farmacia] | Escribano Valenciano, Irene [Farmacia] | Serrano Garrote, Olga [Farmacia] | Ferrari Piquero, José Miguel [Farmacia].
Colaborador(es): Servicio de Farmacia Hospitalaria.
Tipo de material: 
ArtículoEditor: Farmacia hospitalaria: órgano oficial de expresión científica de la Sociedad Española de Farmacia Hospitalaria, 2014Descripción: 38(2):118-22.Recursos en línea: Solicitar documento Resumen: Background and objective: After the marketing of Abiraterone, an androgen synthesis inhibitor, the aim of the study was to analyze its use, response, and safety in the population of a tertiary care level hospital.
Materials and methods: A retrospective observational study was carried out including all patients that were started on Abiraterone within a 21-month period. Demographical, diagnostic, therapeutic, and clinical variables were gathered. The response was assessed through the decreased of PSA as compared to baseline values. To assess the safety, all treatment-related adverse events were recorded.
Results: A total of 45 patients were included of which 88.89% could be assessed for the drug effectiveness. The median baseline PSA value was 457.31 (range 9032-2.81). PSA decrease was ≥ 50%, ≥ 90% and < 30% in 16 (40%), 3 (7.5%) y 20 (50%), respectively. The most common grade 1-2 adverse events were fatigue (35.6%), increased liver enzymes (28.9%), hipokalemia (13.3%) and fluid retention (11.1%).
Conclusions: Abiraterone was a well tolerated drug that has shown to be active in prostate cancer patients previously treated with taxans, so it has been postulated as an alternative in this pathology.
| Tipo de ítem | Ubicación actual | Signatura | Estado | Fecha de vencimiento |
|---|---|---|---|---|
Artículo
|
PC16688 (Navegar estantería) | Disponible |
Formato Vancouver:
Caro Teller JM, Cortijo Cascajares S, Escribano Valenciano I, Serrano Garrote O, Ferrari Piquero JM. Uso, efectividad y seguridad de abiraterona en cáncer de próstata. Farm Hosp. 2014 Apr 1;38(2):118-22.
PMID: 24669896
Contiene 15 referencias
Background and objective: After the marketing of Abiraterone, an androgen synthesis inhibitor, the aim of the study was to analyze its use, response, and safety in the population of a tertiary care level hospital.
Materials and methods: A retrospective observational study was carried out including all patients that were started on Abiraterone within a 21-month period. Demographical, diagnostic, therapeutic, and clinical variables were gathered. The response was assessed through the decreased of PSA as compared to baseline values. To assess the safety, all treatment-related adverse events were recorded.
Results: A total of 45 patients were included of which 88.89% could be assessed for the drug effectiveness. The median baseline PSA value was 457.31 (range 9032-2.81). PSA decrease was ≥ 50%, ≥ 90% and < 30% in 16 (40%), 3 (7.5%) y 20 (50%), respectively. The most common grade 1-2 adverse events were fatigue (35.6%), increased liver enzymes (28.9%), hipokalemia (13.3%) and fluid retention (11.1%).
Conclusions: Abiraterone was a well tolerated drug that has shown to be active in prostate cancer patients previously treated with taxans, so it has been postulated as an alternative in this pathology.
No hay comentarios para este ejemplar.